key: cord-0830408-7a8j38a0 authors: Woods, Patricia; Flynn, Maura; Monach, Paul; Schiller, Sara; Holmberg, Erika; Leatherman, Sarah; Ferguson, Ryan; Branch-Elliman, Westyn title: Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial date: 2021-06-26 journal: Contemp Clin Trials Commun DOI: 10.1016/j.conctc.2021.100804 sha: da63b954ef5464537b599f0528754bd29ab484fe doc_id: 830408 cord_uid: 7a8j38a0 BACKGROUND AND OBJECTIVE: The communicable nature of many infectious diseases, including SARS-CoV-2 creates challenges for implementing and obtaining regulatory-compliant written informed consent. The goal of this project was to identify and evaluate processes that address these barriers while maintaining clinical and research staff safety. METHODS: We reviewed Federal Drug Administration (FDA), World Health Organization (WHO), and VA Office of Research and Development (ORD) guidance about informed consent during the COVID-19 pandemic, and identified and pilot-tested several mechanisms for obtaining regulatory-compliant consent during our COVID-19 therapeutics clinical trial. RESULTS: Several processes were identified. These included a standard face-to-face consent with a plan for maintaining a paper copy of the signed consent form, a phone or video chat consent process that included taking a picture of the signed consent form or a screen shot of the signed document during a video chat, integration of the consent forms into software embedded within the electronic health record, and secure software programs with electronic signature. These processes are FDA-compliant but time-intensive, often requiring four or more hours of coordination between the clinical team, research staff, patients, and legally authorized representatives. CONCLUSIONS: Future studies could evaluate how to improve efficiency, and whether some elements of the consenting process, such as the requirement for documented written signed consent, rather than a witnessed oral consent, is an acceptable standard for research participants with communicable diseases. mechanism for obtaining a signature from the patient, is compliant with federal guidelines about 141 documenting consent to participate in research. Due to challenges with cleaning and 142 disinfection requirements, this option was not pursued. 143 The third process involved collecting a photograph of the patient's signature on the paper 145 informed consent document. This photograph could be obtained using a smartphone, tablet, or 146 other approved and encrypted device, and then printed and stored with other study documents, 147 or scanned into the electronic medical record system. Signature by the person obtaining 148 consent and the witness must also be documented in parallel, similar to the processes laid out 149 above. Alternatively, if consent was obtained via video chat, investigators could take a 150 screenshot of the patient holding up the signed consent form, and that would serve as 151 documentation of signature. We identified similar processes for obtaining consent via a legally authorized representative 158 (LAR), with some variations given that LARs may not be able to enter facilities due to visitor 159 restrictions implemented during the pandemic, and that LARs, unlike patients, may not pose an 160 infection risk to staff if they are able to consent in person. If the LAR is able to come to the 161 medical center and sign the paper consent form, then typical research processes may be 162 followed, without the need for additional workarounds, PPE use, or concern for contamination. If 163 the LAR is remote, or unable to come to the medical center, then the consent form can be 164 emailed to the LAR using an encrypted email service, and the informed consent process 165 J o u r n a l P r e -p r o o f conducted via phone with a witness also on the call. To maintain compliance, the LAR must 166 then print and sign the ICF and return the signature page by email or take a photograph of the 167 ICF document and return it via encrypted software. Either this document is then signed by the 168 person obtaining consent and the witness (to maintain all signatures on one page), or those 169 additional signatures can be on a separate page, as above. Alternatively, the LAR's signature 170 may be witnessed using a video chat platform approved by the institution and compliant with 171 local privacy policies. A snapshot of the ICF is collected, and then the investigator and the 172 witness sign the ICF, attesting that the LAR signed a paper copy of the document remotely. 173 174 Pilot Testing and Implementation: 175 During pilot testing, we attempted to identify processes that would minimize the need for face-176 to-face interactions to limit exposure of staff to patients with COVID-19 disease and to preserve 177 PPE, in light of national shortages. Another goal was to limit the amount of physical paperwork 178 that needed to be saved and collected, to minimize the risk of fomite-based transmission, and 179 also to minimize the need for a "decontamination period" wherein the paper copy was stored 180 and then collected at a later time to minimize the risk that relevant study documents would be 181 lost or misplaced. In addition, we sought to estimate the average length of time required to 182 complete the guideline-compliant informed consent process. 183 Of note, our facility has an iPad program for admitted patients with COVID-19, thus this tool is 185 universally available in our facility for patients who do not require a legally authorized 186 representative (LAR) to participate in the informed consent process. Based on these barriers, and FDA regulatory guidance, we identified four independent 194 processes that could be used to collect written informed consent (Figure 1) . All strongly 195 emphasized limiting staff exposure and need for PPE use. Critical to all options, in accordance 196 with FDA guidance, either the patient or the LAR required access to a physical copy of the 197 informed consent document. This could be provided in paper form to the patient or the LAR at 198 the treating facility or provided via fax or email to a LAR who was not on-site. 199 Benefits of the first process, which involved a standard paper consent form and a non-remote 201 consenting process, included that the signed form is able to be copied and provided directly to 202 pharmacy without concern for contamination. Short turnaround time between obtaining 203 documentation of consent and provision of documentation to pharmacy speeds the process of 204 release of study drug and ultimately administration of the study drug to the patient. Downsides 205 of this process include the need to use limited PPE to enter the patient's room, unnecessary 206 possible exposure of providers and investigators to SARS-COV-2, and the potential to lose the 207 physical copy of the document during the storage and future collection process; however, this 208 may be mitigated if the document is able to be decontaminated and quickly scanned into an 209 electronic format, as is the case if a clear plastic bag is used. A benefit of this adapted standard 210 approach is that it may be the fastest mechanism to obtain consent, as few technological 211 transfers are required. 212 The second process, involving remote consent, was the most commonly used strategy (13/15 214 consents). During the conduct of our trial, we found that, given inherent challenges on the 215 closed inpatient COVID-19 unit, this process was substantially more feasible after we introduced 216 J o u r n a l P r e -p r o o f informed consent packets, which included all regulatory documents and a pen, stored in a 217 plastic bag on the unit for easy distribution to the patient and cleaning. 218 219 Electronic consenting platforms already integrated into the EHR, were not used in our facility. A 220 barrier to using this process for obtaining consent for participation in research was the need to 221 minimize contamination, cleaning and disinfection of portable electronic systems, which might 222 be used by many different patients, and therefore pose an infection control risk if SARS-CoV-2 223 patients used the system directly. Although we did not pursue this approach, a benefit of this 224 strategy is that a note is automatically generated within the EHR and serves as documentation 225 that the process occurred. However, because signing with an "X" on behalf of the patient is only 226 permitted for compassionate use, challenges about cleaning and decontaminating the portable 227 electronic system remain. 228 The third process involved obtaining a photograph of the patient's signature on the paper 230 informed consent document. We found that challenges of this strategy included: 1) available 231 iPads did not have picture-taking capability, thus were of limited utility for obtaining proof of 232 written consent, and 2) pictures taken were often of low-quality, making discerning of signatures 233 difficult, and/or did not include the IRB stamp and approval date in the picture field, requiring 234 additional documentation attempts prior to receiving adequate documentation of written consent 235 for compliance with research regulatory procedures. Additionally, many of the patients enrolled 236 in our trial were quite ill, and were often weak and trembling, making collection of a regulatory-237 compliant photograph challenging. 238 239 A final option we explored was the use of DocuSign 12 or similar electronic signature systems to 240 obtain signed consent, either from the patient or from their LAR. Due to regulations and 241 information security controls within the VA while our trial was open and enrolling, we were not 242 J o u r n a l P r e -p r o o f able to use this process in our facility; however, its use for both COVID and non-COVID 243 research may be a possibility for other institutions with access to this software or similar 244 software. 13 Such signature systems can be used on any smart phone or electronic device, 245 including computers; thus, many potential participants will have access and be able to 246 participate. As with the other options presented, this is also a touchless system that does not 247 require the use of additional PPE, or the need to place staff at risk, in order to obtain a legal 248 signature. For an off-site LAR, access to technology at the level of a smart phone or email is 249 necessary, but email access is also needed to deliver the informed consent form, so use of an 250 approach like DocuSign is not an additional barrier. In addition, an actual physical copy of the 251 paper document is not required, as the system is fully electronic and thus there is no potential 252 exposure to clinical or research staff, and no need for additional PPE. In total, after the FDA issued updated guidance about the informed consent process for COVID-256 19 clinical trials, we conducted informed consent remotely with 13 patients and 2 LARs at our 257 facility; documentation of written consent was obtained using the scanning method for 7 258 participants, 3 participants took a photo of the signed documents and emailed them back to 259 study staff and for 5 participants study staff took a photo of the consent forms. A summary of the 260 benefits and downsides to different processes is presented in Table 2 . 261 262 Overall, we found that the informed consent discussion with the patient for the study required 264 approximately 10 minutes, with 5 additional minutes for questions. However, the entire process 265 for documenting and completing informed consent took on average 4 hours, as a result of 266 J o u r n a l P r e -p r o o f difficulties with providing a physical copy of the ICF to the patient, identifying the appropriate 267 LAR and then coordinating with that individual, and transferring the materials required to 268 demonstrate proof of written informed consent. Of note, regulations at our facility included a 269 provision that the patient be allowed to decline contact by the research team before receiving 270 informed consent documents and receiving more detailed information about the study from 271 study team members, which also contributed to prolonging the consenting process. Even the seemingly small task of providing patients with the paper packets required close 280 coordination with their nursing and clinical teams. During the period when the unit was a closed 281 COVID-19 unit, this process was fairly straightforward, however, it was more complicated when 282 the unit was not fully dedicated to COVID-19, and providing research regulatory documents to 283 patients required an additional room entry with full donning and doffing of PPE, or waiting until 284 the clinical care providers were planning to enter the room for another reason. This delay was 285 often compounded by the fact that clinical teams often rounded on the COVID-19 ward last, or 286 later in the day, and the study team was not permitted to contact potential participants until after 287 the clinical team received permission for members of the research team to contact the patient 288 and then conveyed that permission to the study team. Additional causes for delays in the 289 informed consent process included that patients were often very tired and worn out due to their 290 underlying diagnosis and admission processing, and thus not up to reviewing research 291 documents when they were initially approached. Other delays may have been caused by other 292 activities, such as meals, which patients preferred not to have interrupted. When LARs were 293 involved in the consenting process, they were often compelled to consult with other family 294 members prior to making a decision about enrolling their loved one in the study, also leading to 295 additional phone calls and lengthening the process. Finally, after the patients consented to 296 enrollment, there was a wait period to compile and transfer research regulatory documents, and 297 a waiting period for a study team member to go to the medical center, don PPE, collect the 298 form, doff PPE, and then scan or take a picture of the paper form. 299 300 In the setting of a global pandemic with a highly transmissible and potentially fatal novel 302 infection, there is a significant burden on clinicians, investigators, patients, and their LARs in 303 obtaining written signed informed consent that is fully compliant with current federal guidance. 304 Outbreaks includes a provision that research should not drain critical health-related resources. 14 306 In conducting our clinical trial, we found that the process of requiring paper documents and 307 written informed consent required an average of 4 hours of logistical coordination by clinical and 308 study staff, a substantial burden on an already overwhelmed system. This time was primarily 309 spent identifying ways to gather proof of a "wet signature," and transfer and store paper and 310 electronic documents. The WHO guidance recommends that patients in isolation have the time 311 and opportunity to discuss clinical trial options with their loved ones, which is critical for informed 312 participation in research, however, the delays in our trial were due to time spent addressing 313 administrative and process barriers, not counseling patients or their family members. Collection of potentially contaminated paper hours to days after consent is obtained. Limited availability of technology to support informed consent process to patient or legally authorized representative (e.g., LAR lacks a printer, scanner, smart phone, computer, or a fax machine) We were not able to identify a solution. Witnessed phone consent was a possibility, however, is only currently accepted for clinical consents and not for participation in a clinical trial. Distribution of paper copy of informed consent to the patient Consent forms pre-printed and available on nursing units. Distribute consent forms to all patients admitted to COVID-19 units. Provide informed consent documents to treating teams to distribute during morning rounds, to limit the need for additional room entries and exists and personal protective equipment use. Patients gravely ill/too ill to provide consent Screen and consent patients prior to eligibility. 508 509 J o u r n a l P r e -p r o o f Face-to-face interaction may engage the patient more effectively in the informed consent process. Study staff using personal protective equipment (PPE) that was limited in supply and prioritized for clinical use. Study staff may be able to better communicate with patient and gauge their understanding of study information. Potential exposure of study staff to SARS-COV-2. Study staff were able to assess the patient's physical condition and ability to tolerate the timing of the informed consent process (some patients were easily fatigued or coughing). No technology hurdles to overcome. A more positive/satisfying experience for patient. Study staff were not put at risk of potential exposure to SARS-COV-2. Consent conducted by phone may be less personal and limits the ability of study staff to assess the patient's condition and non-verbal response to the information presented. Process provided a successful option for conducting the informed consent process and meet the FDA/VA requirements for obtaining documentation of informed consent. Technical challenges: identifying available resources, learning the use of equipment, determining permitted methods to transfer documents. Reliance/added burden on nursing staff to support research staff; access to iPad, providing consent form to patient, removing signed form from patient's room. Hearing Impairment -some patients were unable to hear on the phone. Logistical challenges encountered J o u r n a l P r e -p r o o f with coordinating/scheduling calls with patients/LARs/witnesses. More burdensome on patientasking patient to place signed documents in plastic bag or instructing patient to take a photo of the signature pages and send to study staff via encrypted email. Quality of photo/scanned document was poor and required repeating. More difficult to guide patient in completing form particularly amongst those of advanced age. Study staff may not note discrepancies in completing the document at the time of consent, e.g., incorrect date or date placed in wrong location on form. Remote Consent conducted by phone or video with a photograph or scan of the signed signature page Valuable option to engage LARs (who due to COVID could not be present with their family member) and provide their loved one an opportunity to participate in a research study. Technical barrier -LAR needed to have access to email and a printer. (In one instance, staff drove to LARs location to provide documents and obtain signature). More burdensome to LAR -LAR needed to print, sign and scan/take photo of signed document and return to study staff via encrypted email. Clinical characteristics of coronavirus disease Covid-19: the crisis of personal protective equipment in the US Critical supply shortages-the need for ventilators and 448 personal protective equipment during the Covid-19 pandemic Human Subjects Protection Issues Related to COVID-19: Frequently Asked Questions Human Subjects Protection Issues Related to COVID-19 FDA guidance on conduct of clinical trials of medical 455 products during COVID-19 pandemic: guidance for industry, investigators, and institutional 456 review boards VA Office and Research and Development. Spring Research Town Hall Bringing New Meaning to the Term Challenges of Conducting Clinical Research during the COVID-19 Pandemic and 465 Implications for Implementation Science. Open Forum Infect Dis Profile of sarilumab 467 and its potential in the treatment of rheumatoid arthritis. Drug design, development and therapy Racial and ethnic disparities in parental refusal of 470 consent in a large, multisite pediatric critical care clinical trial. The Journal of pediatrics Research in the time of coronavirus: continuing ongoing studies in the midst of 473 the COVID-19 pandemic World Health Organization. Guidance for managing ethical issues in infectious disease 475 outbreaks Reams of Useless COVID Data Drive Reckoning on Clinical Trials North CM, Dougan ML, Sacks CA. Improving Clinical Trial Enrollment -In the Covid-19 Compassionate Use of Remdesivir for Patients with 487 Severe Covid-19 COVID-19: interim guidance on management 490 pending empirical evidence. Last updated Observational Study of Hydroxychloroquine in 492 Hospitalized Patients with Covid-19 United States veterans hospitalized with Covid-19. medrxiv Hydroxychloroquine or chloroquine with 497 or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet Hydroxychloroquine or 500 chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry 501 analysis. The Lancet receiving the drug in therapeutics trials. Further, in trials in which use of other medications is not 368 prohibited, patients randomized to standard of care are not subject to greater risk than patients 369 who are not involved in any trial or compassionate use program. We do not argue that the 370 process of informed consent to participate in research should be compromised, but rather that 371 its documentation should not be made more arduous -for the patient -than it is for open-label 372 use of an unapproved drug. 373 In identifying ways to address the barriers posed by the need for documented consent, we 375 found that coordination with the clinical teams caring for COVID-19 patients was even more 376 important than usual, for several reasons. First, the treating clinicians were aware of which 377 patients were eligible, and which might become eligible for participation. Second, the treating 378 teams were donning PPE and seeing the patient anyway, so the additional burden of providing 379 potentially eligible patients a paper copy of a consent form while on rounds was minimal. 380Indeed, given the very limited treatment options for patients with COVID-19, we found our 381 clinical partners to be highly engaged and enthusiastic supporters of the research study and that 382 they were willing to facilitate the process. A barrier to this process was the frequent change and 383 turn-over on clinical teams. To address this, the study team reached out to attendings as they 384 rotated onto the COVID-19 service, introducing them to the study, and clarifying their role. 385Despite this intervention, we found variable support with different teams and attendings, 386 impacting both the time required to obtain informed consent and also receipt of permission from 387 patients to contact them about the study. 388 389 Importantly, due to the rapidly progressive nature of COVID-19, we included a provision that 390 patients could be screened and consented before meeting eligibility for randomization. This was 391 a critical facilitator for enrolling patients because the informed consent process was time-392 J o u r n a l P r e -p r o o f intensive, and patients with COVID-19 may decompensate quickly. Thus, there was a short 393 window in which patients met eligibility criteria without being too sick to engage in the research 394 study. In addition, we found that obtaining informed consent, due to the processes involved, was 395 often challenging for patients who were critically or near-critically ill; thus, it was less 396 burdensome for the patient to complete the informed consent process prior to eligibility, and 397 then to randomize patients if they clinically worsened to the point they were eligible for 398 participation in our trial. 399 400 Although we were able to identify many work-arounds, we were not fully able to address the 401 case of patients who were unable to provide informed consent themselves, and who either did 402 not have a LAR, or had a LAR who did not have access to the relevant technology (e.g., no 403 smart phone, tablet, computer, printer, or fax machine), and who were not able to travel to the 404 medical center to participate in a traditional paper consenting process. Under the current federal 405 guidance supporting documented signed consent, patients whose LAR lacks amenities such as 406 a printer, scanner, or mobile phone able to send and receive encrypted images, are unable to 407 participate, or undue burden is placed on the LAR to seek access to the relevant technology. 408Although consent forms could be sent via mail, this option leads to additional delays providing 409 any treatments to the patient, which may ultimately render them ineligible for the clinical trial. As ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:All authors have no conflicts of interest to report. WBE is supported by NHLBI 1K12HL138049-01.J o u r n a l P r e -p r o o f